Interviewing patients can help you in choosing the most relevant patient-reported outcome measures to apply in your clinical trials. Patient-reported outcome measures (PROMs) are frequently applied…Read More
Can you set a strong marketing strategy without hearing what users think about your investigational drug?
Get a clearer picture of your investigational drug prior to market launch. Interestingly, the pharmaceutical industry has remained one of the few industries where direct user feedback is not…Read More
EMA wants to strengthen the collaboration with HTAs to reinforce patient relevance in evidence generation
Highlights on EMA’s focus to advance patient-centred access to medicines in partnership with healthcare systems. In EMA’s Regulatory Science Strategy to 2025, the EMA presents...Read More
Increased interest from EMA to enhance the incorporation of patients’ voices into drug development. As part of the EMA’s Regulatory Science Strategy to 2025, EMA proposes…Read More
Are you developing drugs in accordance with regulatory guidances on Patient-Focused Drug Development?
The FDA and the EMA are strengthening Patient-Focused Drug Development. The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) both acknowledge that…Read More
The limitations of Patient Reported Outcome Measures (PROMs). Traditional PROMs (consisting of closed-end questions) have for many years been applied to reveal the patients’ experiences of effects…Read More